Prochymal Approval Status
- FDA approved: No
- Brand name: Prochymal
- Company: Osiris Therapeutics, Inc.
- Treatment for: Graft-versus-Host Disease
Prochymal is a preparation of mesenchymal stem cells specially formulated for intravenous infusion. Prochymal is currently being evaluated in Phase III trials for steroid refractory graft-versus-host disease (GvHD), acute GvHD, and Crohn's disease.
FDA Approval Status for Prochymal
|Jan 15, 2009||Osiris and FDA Reach Agreement on Submission of First Marketing Application for a Stem Cell Product|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.